Miragen Therapeutics, Inc. (NASDAQ:MGEN) Q2 2020 Earnings Conference Call - Final Transcript

Aug 05, 2020 • 04:30 pm ET


Miragen Therapeutics, Inc. (NASDAQ:MGEN) Q2 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Greetings, and welcome to the Miragen Therapeutics Q2 2020 Earnings Conference Call. [Operator Instructions]

I will now turn the conference over to Dan Ferry of LifeSci Advisors. Thank you. You may begin.

Dan Ferry

Thank you, operator. Good afternoon, everyone, and welcome to our second quarter 2020 conference call. Today, after the market close, we issued a press release providing our second quarter financial results and business updates. A replay of today's call will be available on the Investors section of our website approximately one hour after its completion. After our prepared remarks, we will open up the call for Q&A.

Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of today. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our most recent filings on Form 10-K and our other periodic reports on Forms 10-Q and 8-K filed with the SEC.

I would now like to turn the call over to Dr. Bill Marshall, Miragen's President and Chief Executive Officer.

William S. Marshall

Thank you, Dan. Good afternoon, everyone, and thank you for joining us for our corporate update call for the second quarter 2020. I'm joined today by the rest of our leadership team; Diana Escolar, our Chief Medical Officer; Jason Leverone, our Chief Financial Officer; and Lee Rauch, our Chief Operating Officer.

First, I would like to express my gratitude and appreciation to the whole Miragen team for all that they are doing to help advance microRNA-targeted therapies as a potential new class of medicines. At Miragen, we believe in the potential of therapeutic microRNA targeting and in our ability to develop potentially transformative medicines for patients in need across a wide range of diseases.

Before I hand the call over to Diana to provide a review of our programs, I would like to take this opportunity to talk about Miragen's progress and our expectations going forward. I'm pleased with our business performance on multiple fronts and encouraged by the continued commitment of our team to deliver results during these challenging times. As we enter the second half of the year, we believe we are on track to achieve many of our 2020 goals, which will help position the company for future growth and continued innovation.

During the first half of 2020, we released clinical data for cobomarsen in Adult T-Cell Leukemia/Lymphoma or ATLL, which we believe supports the continued development in this indication. We are scheduled to meet with the FDA to present our data and discuss the development path for cobomarsen in ATLL and expect to receive their guidance